OBJECTIVE: Low @entity2124 ( @entity2124 ) secretion and @entity6126 are common in @entity1 with @entity6038 ( @entity6038 ). In this study we present the effects of @entity2124 treatment on body composition and metabolism in adults with @entity6038 . @entity1 AND MEASUREMENTS: Nineteen @entity1 with clinical @entity6038 were recruited, 13 had @entity6038 genotype. They were randomised to treatment with placebo or @entity2124 (Genotropin, Pharmacia Corporation, Sweden) 0.8 IU (0.2 mg) daily for 1 month and then 1.6 IU (0.5 mg) daily for 5 months. Thereafter @entity1 received open label treatment so that all had 12 months of active @entity2124 treatment. Doses were individually titrated to keep serum @entity442 within the normal range for age. Body composition using dual energy X-ray absorptiometry (DXA), @entity209 , including oral @entity413 tolerance test (OGTT), were studied every 6 months. Seventeen @entity1 , nine @entity1 and eight @entity1 , 17-32 years of age, with a mean body mass index (BMI) of 35 +/- 3.2 kg/m2 completed the study. RESULTS: Compared to placebo, @entity2124 treatment increased @entity442 (P < 0.01) levels and decreased body fat (P = 0.04). When all @entity1 recieved @entity2124 treatment a mean reduction in body fat of 2.5% (P < 0.01) concomitant with a mean increase in lean body mass of 2.2 kg (P < 0.05) was seen. Significant changes in body composition were only seen in the @entity1 with the @entity6038 genotype. Lipid profiles were normal in most @entity1 before treatment and did not change. OGTT was impaired in five @entity1 at 12 months, but two of these @entity1 increased in fat mass. Insulin levels were unchanged. According to homeostasis model assessment (HOMA), insulin resistance did not change. Side-effects attributed to water retention occurred in three @entity1 , one of whom had to be given increased diuretic therapy. CONCLUSION: This study shows beneficial effects of @entity2124 treatment on body composition in adult @entity6038 @entity1 without significant side-effects. Consequently, further studies are encouraged.

XXXX treatment improves body composition in adults with @entity6038 .

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'PATIENTS', 'men'] @entity442 :: ('3479', 'Gene') :: ['IGF-I'] @entity2124 :: ('2688', 'Gene') :: ['GH', 'growth hormone'] @entity6126 :: ('MESH:D007006', 'Disease') :: ['hypogonadism'] @entity209 :: ('MESH:D008659', 'Disease') :: ['metabolic and endocrinological parameters'] @entity6038 :: ('MESH:D011218', 'Disease') :: ['PWS', 'Prader-Willi syndrome'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']
@entity2124 :: (2688,Gene) :: ['Growth hormone']
